Abstract | BACKGROUND: METHODS: We searched the PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials databases for relevant literature, up to February 2020. The data were collected from randomized controlled trials on regorafenib, trifluridine/tipiracil, or fruquintinib, administered to patients with metastatic colorectal cancer who failed on treatment with oxaliplatin, irinotecan, or fluoropyrimidine. The primary end points, namely, the overall survival and progression-free survival, were analyzed for subsequent network analysis using the Review Manager and Aggregate Data Drug Information System software for performing direct and indirect comparisons. RESULTS: CONCLUSION:
|
Authors | Zhenzhen Gao, Chenxi Cao, Yi Bao, Yaohua Fan, Gang Chen, Peng Fu |
Journal | Technology in cancer research & treatment
(Technol Cancer Res Treat)
2020 Jan-Dec
Vol. 19
Pg. 1533033820943241
ISSN: 1533-0338 [Electronic] United States |
PMID | 32914703
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Chemical References |
- Protein Kinase Inhibitors
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Colorectal Neoplasms
(drug therapy, etiology, pathology)
- Disease Management
- Humans
- Molecular Targeted Therapy
(methods)
- Neoplasm Metastasis
- Neoplasm Staging
- Odds Ratio
- Protein Kinase Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Publication Bias
- Treatment Outcome
|